Exelixis, Inc. EXEL
NASDAQ · United States · Health Technology
$57.94-0.47 (-0.80%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Big Money pushes Exelixis, Inc. (EXEL) shares higher by 149% since 2017.
FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.
Exelixis (NasdaqGS: EXEL) said the FDA has extended its review of zanzalintinib plus atezolizumab for metastatic colorectal cancer. The agency lengthened the decision timeline after Exelixis submitted a major amendment with updated safety and efficacy data. The extended FDA review tied to new zanzalintinib safety and efficacy information only captures part of what matters today. Check out 4 other big wins that Exelixis investors should know about. To put this regulatory update in context,...
Exelixis, Inc. (NASDAQ:EXEL) disclosed in a September 11 filing that the FDA had extended the review of zanzalintinib by three months, setting a new target action date of March 3, 2027. The September 10 notification followed an FDA request for updated safety and efficacy information. The submitted data were classified as a major amendment. The […]
The FDA told Exelixis on Thursday that it had extended the review of a new drug application for zanzalintinib plus Roche’s Tecentriq in patients whose colorectal cancer has spread.
Exelixis stock dropped out of a buy zone Friday after the FDA delayed the potential approval of its new colon cancer treatment.
Exelixis Inc (NASDAQ:EXEL) shares fell 3. 5% in premarket trading Friday after the company said the US Food and Drug Administration extended the review period for its new drug application for zanzalintinib by three months.
Meanwhile, several stocks showed bullish signs, including software giant ServiceNow. Digital bank Dave Inc., commodities trading platform Marex Group, senior living REIT Welltower and cancer treatment developer Exelixis round out the list of stocks to watch in or near buy zones. ServiceNow is in a buy zone after breaking out of a cup base with a buy point of 139.20 on Aug. 28, reclaiming the entry on Sept. 2.
Exelixis is Friday's IBD Stock Of The Day. Shares have recovered from a post second-quarter drop and are now trading in a buy zone.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.